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Abstract
Background: Health service change is difficult to achieve. One strategy to facilitate such change is the clinical
pathway, a guide for clinicians containing a defined set of evidence-based interventions for a specific condition.
However, optimal strategies for implementing clinical pathways are not well understood. Building on a strong
evidence-base, the Psycho-Oncology Co-operative Research Group (PoCoG) in Australia developed an evidence and
consensus-based clinical pathway for screening, assessing and managing cancer-related anxiety and depression
(ADAPT CP) and web-based resources to support it - staff training, patient education, cognitive-behavioural therapy
and a management system (ADAPT Portal). The ADAPT Portal manages patient screening and prompts staff to
follow the recommendations of the ADAPT CP. This study compares the clinical and cost effectiveness of two
implementation strategies (varying in resource intensiveness), designed to encourage adherence to the ADAPT CP
over a 12-month period.
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Methods: This cluster randomised controlled trial will recruit 12 cancer service sites, stratified by size (large versus
small), and randomised at site level to a standard (Core) versus supported (Enhanced) implementation strategy.
After a 3-month period of site engagement, staff training and site tailoring of the ADAPT CP and Portal, each site
will “Go-live”, implementing the ADAPT CP for 12 months. During the implementation phase, all eligible patients
will be introduced to the ADAPT CP as routine care. Patient participants will be registered on the ADAPT Portal to
complete screening for anxiety and depression. Staff will be responsible for responding to prompts to follow the
ADAPT CP. The primary outcome will be adherence to the ADAPT CP. Secondary outcomes include staff attitudes
to and experiences of following the ADAPT CP, using the ADAPT Portal and being exposed to ADAPT
implementation strategies, collected using quantitative and qualitative methods. Data will be collected at T0
(baseline, after site engagement), T1 (6 months post Go-live) and T2 (12 months post Go-live).
Discussion: This will be the first cluster randomised trial to establish optimal levels of implementation effort and
associated costs to achieve successful uptake of a clinical pathway within cancer care.
Trial registration: The study was registered prospectively with the ANZCTR on 22/3/2017. Trial ID
ACTRN12617000411347
Keywords: Implementation, Clinical pathways, Cancer, Anxiety and depression, Cluster randomised controlled trial,
Health services, Psycho-oncology
Background
Anxiety and depression are the third largest causes of
disability in Australia, impacting on family and social
functioning, work performance, suicidal ideation, and
survival [1, 2]. Rates of anxiety and depression are sig-
nificantly higher in cancer patients than in the general
population with point prevalence estimates of 20.7% for
any mood disorder [3]. Despite high acceptance that psy-
chosocial care is integral to quality cancer care, anxiety
and depression are often undetected and their impact on
patients under-estimated [4] in busy cancer services.
Consequently a high unmet need for psychosocial care is
persistent in cancer patients [5], despite the large
evidence-base that interventions for anxiety and depres-
sion in patients with cancer are effective in the short
and long-term [6, 7].
Because anxiety and depression are often under-de-
tected, routine screening of all cancer patients for psy-
chological distress using validated, reliable, objective
measures, is internationally endorsed [8]. The Inter-
national Psycho-Oncology Society (IPOS) and 68 affili-
ated organisations have set a standard of care that calls
for monitoring distress as the “6th vital sign”. In Canada,
cancer services have demonstrated that national screen-
ing of patients for distress is acceptable, feasible, and can
be implemented [9], yet in Australia screening is not
standard practice, and occurs to a variable extent across
services.
Screening and detection, however, are only part of the
solution. Several recent systematic reviews [10–12]
highlighted the most significant predictor of improved
patient outcomes as receipt of appropriate care after
screening [10, 12]. Yet in the studies evaluated, only one
in three patients received treatment after a positive
screen for distress. In Australia, patterns of referral,
treatment and follow-up of detected anxiety and depres-
sion vary across services. To address under-referral and
inadequate management, a clear, empirically validated,
clinical pathway to manage anxiety and depression is
needed. Clinical pathways are standardised, evidence-based
multidisciplinary management plans, which identify an
appropriate sequence of clinical interventions, timeframes,
milestones and expected outcomes for one or more patient
groups. Clinical pathways have been shown to improve
patient outcomes [13].
ADAPT clinical pathway: background and development
A clinical pathway for screening, assessment and
management of anxiety and depression in adult cancer
patients (ADAPT CP) was developed to guide best
practice in Australia [14]. The ADAPT CP is based on a
review of the evidence and was refined through compre-
hensive stakeholder review and a Delphi consensus
process [15]. Self-management and patient empower-
ment are built into the ADAPT CP and are important
principles underlying its structure. The ADAPT CP fol-
lows a stepped care model incorporating iterative
screening at recommended intervals, with triage to one
of five steps (from universal care and self-management
for those with minimal or mild levels of anxiety and/or
depression, to specialist care for those with severe
anxiety and/or depression), with review and change in
step where necessary. Evidence-based recommendations
on staff responsibilities, and content and timing of
interventions, are provided for each step and tailored to
available resources [14].
The ADAPT CP recommends formalised routine
screening for anxiety and depression using the Edmonton
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Symptom Assessment System (ESAS-R) [16] or Distress
Thermometer (DT) [17] as brief screening tools,
combined with a more detailed tool, such as the Hospital
Anxiety and Depression Scale (HADS) [18], to identify
likely caseness (a clinical diagnosis). A structured clinical
interview is required to confirm diagnosis.
While clinical pathways have shown considerable suc-
cess in bringing about change in patient management,
the context and implementation strategies utilised when
introducing them into routine care are critical to success
[19, 20]. Failed intervention implementation efforts can
disrupt work flows, add significant staff burden and
increase staff resistance to future interventions [21]. The
Promoting Action on Research Implementation in
Health Sciences (PARiHS) framework posits that suc-
cessful implementation occurs when evidence is robust,
the context receptive to change, and the change process
appropriately facilitated with care taken to address bar-
riers [22]. We conducted a barrier analysis [23] which,
similar to studies outside the cancer setting [24, 25],
identified lack of resources, education and training and
support from leaders, poor uptake by patients, and lack
of integration within the community, as key.
ADAPT resources
In response to these identified barriers, our team devel-
oped and tested a number of online resources to support
implementation of the ADAPT CP, including a web-based
management system to operationalise the pathway tai-
lored to site-specific staffing and resources (the ADAPT
Portal), patient education materials, health professional
education modules and an online cognitive-behavioural
therapy program for anxiety and depression in patients
with cancer (iCanADAPT) [26].
The ADAPT Portal prompts patients to complete
validated screening and assessment questionnaires; alerts
health professionals by system flags and email when a
patient has elevated anxiety or depression; describes the
pathway relevant to that individual patient and appropri-
ate staff responses; provides standardised templates for
referral and progress review to/from mental health
services when required; and schedules ongoing follow
up screening of patients at pivotal times/visits. The
ADAPT Portal was pilot-tested in early 2017 (paper
under review) and shown to be feasible, technically
operational and acceptable.
The ADAPT patient education materials explain the
importance of screening for anxiety and depression, the
process involved for patients in the use of the ADAPT
CP and Portal, and links to existing patient/caregiver
resources about cancer-related anxiety and depression.
A pilot study using qualitative methods with 20 current
cancer patients and survivors showed the materials to be
acceptable, and at an appropriate reading level (paper
under review).
The ADAPT online health professional education modules
were developed using evidence-based learning principles
and spaced education to promote interactive learning. This
education targets screening, assessing severity, making a
referral - particularly when patients are reluctant - and
empathic communication. Modules are available on eviQ
Cancer Education Online (www.eviq.org.au), a widely used
Oncology education site in Australia, via links in the
ADAPT Portal. These education modules were pilot tested
in a pre-post simulation study with 12 Oncology nurses
and found to be acceptable, feasible and to associated with
increased skills (paper in preparation).
A program delivering online cognitive-behavioural
therapy for anxiety and depression has been developed
for patients with early stage cancer (iCanADAPT Early).
The therapy includes behavioural activation, cognitive
restructuring and problem solving, and mindfulness
strategies, completed in 6–8 sessions over 10–12 weeks.
This online program is available in the ADAPT Portal
for patient self-referral or clinician referral. Participants
complete a short screening instrument (the K-10) [27]
before each online lesson. A clinical psychologist
monitors the progress of participants enrolled in iCa-
nADAPT and contacts those with persistently elevated
scores to assess need for referral to face-to-face
therapy. iCanADAPT Early has been piloted [26] and
evaluated in a randomised controlled trial and shown
to be effective in reducing anxiety and depression
compared to a care-as-usual control group (paper
under review).
Implementing the ADAPT clinical pathway in cancer services
There is a growing evidence-base that various strategies
(such as presenting evidence that the intervention is
effective; local, respected champions to promote the
intervention; systems that reduce the burden of imple-
mentation as much as possible; and ongoing audit and
feedback on implementation adherence and success) in-
crease the likelihood of successful implementation [28].
However, there is little clarity regarding the optimal
combination and dose effect of implementation strat-
egies, and almost no data about the costs of implemen-
tation. Without such data it is difficult for health
systems to incorporate CPs into routine delivery of care.
In this study we aim to determine the optimal “dose”
of implementation effort and cost required to effectively
achieve adherence to the ADAPT CP. Thus, cancer
services participating in the study will be randomised to
a standard (Core) implementation strategy versus a
supported, tailored (Enhanced) implementation strategy
for the ADAPT CP.
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Methods and design
Primary objective
The primary objective of the ADAPT Cluster randomised
controlled trial (Cluster RCT) is to evaluate the efficacy
and cost-effectiveness of two implementation strategies
(Core versus Enhanced) in achieving adherence to the
ADAPT CP.
Secondary objectives
Secondary objectives are to:
i. describe adherence to each component of the
ADAPT CP and predictors of adherence
ii. describe the acceptability, adoption,
appropriateness, feasibility and fidelity of individual
implementation strategies and resources used to
support implementation of the ADAPT CP in
cancer services in NSW
iii. evaluate staff and patient acceptability of the
ADAPT CP, within a NSW health context
iv. describe the costs of the ADAPT CP and compare
the costs of the two implementation strategies
(Core vs. Enhanced) used to facilitate uptake
of the ADAPT CP
v. evaluate the cost effectiveness of two
implementation strategies (Core vs. Enhanced) used
to facilitate uptake of the ADAPT CP
vi. describe levels of anxiety and depression of patients
participating in the ADAPT CP over a 12-month
period, and patients’ allocation to five clinical,
subclinical and non-clinical categories of anxiety
and depression by staff
vii. describe referral patterns of cancer services before
and after the introduction of the ADAPT CP,
including uptake of referrals by patients.
Hypotheses
(Note, methods used to measure each outcome referred
to in the hypotheses are described in the Measures
sub-section of the Methods and design section below.)
Primary hypothesis
Adherence to the ADAPT CP (yes/no, defined as having
completed 70% or more of the recommended ADAPT
CP components) will be greater in the Enhanced imple-
mentation arm than in the Core implementation arm.
Secondary hypotheses
Adherence to the ADAPT CP and predictors of
adherence
1. Adherence to each component of the ADAPT CP
(yes/no) will be greater in the Enhanced
implementation arm than in the Core
implementation arm.
2. Adherence to the ADAPT CP will increase from
the 6- to 12-month follow-up.
3. Staff-perceived individual and site readiness to
change will be associated with adherence to the
ADAPT CP.
4. Staff use of the ADAPT resources will be associated
with adherence to the ADAPT CP.
5. Characteristics of the service (size, psychosocial
staffing, existing psychosocial screening), will
influence staff attitudes and adherence to the
ADAPT CP.
6. Greater awareness/use and perceived utility of
implementation strategies will be associated with
better adherence to the ADAPT CP.
Acceptability of the ADAPT CP and resources
7. The ADAPT CP will be acceptable to staff and
patients.
8. At least 60% of staff will be aware of, use, and rate
as useful, the ADAPT resources (including the
health professional training and the ADAPT Portal).
ADAPT implementation strategies (Core and Enhanced)
9. Both Core and Enhanced ADAPT implementation
strategies will be feasible (delivered) and delivered
with fidelity as planned.
10. At least 60% of staff will be aware of, use, and rate
as useful, both Core and Enhanced ADAPT
implementation strategies.
11. Acceptability, adoption, appropriateness, feasibility,
fidelity, and penetration of implementation
strategies will be greater in the Enhanced
implementation arm than the Core implementation
arm.
12. Improvements in staff-reported acceptability of the
ADAPT CP and perceived readiness to change will
be greater at 6- and 12-month follow-ups in the
Enhanced implementation arm compared to the
Core implementation arm.
Cost-effectiveness
13. While more costly, the Enhanced implementation
arm will achieve greater adherence than the Core
implementation arm.
Patient outcomes
14. Anxiety and depression screening scores at
rescreening will be significantly lower than at the
initial screen.
Study design and setting
The study is a Cluster RCT being undertaken in the
state of New South Wales (NSW), Australia. NSW
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health services are managed through 15 local health
districts and three specialty networks. Twelve cancer
services will be stratified by size of service - large (≥100
new pts./year) versus small (< 100 new pts./year)) to
ensure equal patient volume in the two study arms. The
sites will then be randomised at the cancer service level
to a Core implementation strategy arm versus an
Enhanced implementation strategy arm to facilitate
uptake of the ADAPT CP.
After a 3-month period of site engagement, staff train-
ing and tailoring of the ADAPT CP and ADAPT Portal
for each participating cancer service (site), that site will
“go-live” and implement the ADAPT CP for 12 months,
as part of routine care. ADAPT research staff will deliver
the Enhanced or Core implementation strategies over
that period, according to randomisation. The study uses
a mixed methods design. Both quantitative and qualita-
tive data eliciting staff attitudes to and experiences of
the ADAPT CP and implementation strategies utilised,
will be collected at T0 (baseline - after site engagement,
at ADAPT go-live), T1 (6 months post go-live) and T2
(12 months post go-live).
Taking into account the governance, engagement and
implementation phases, each site will participate in the
study for a period of 18 months. Three sites will be acti-
vated every 3 months. Thus, all sites will have completed
the study over a 30 month/2.5-year period.
Inclusion criteria
Cancer services will be eligible to participate if they
provide care for at least 100 patients per year in NSW
Australia. Eligible cancer services may operate within
the public or private healthcare system. They may be
whole services or single departments within services,
such as tumour streams (e.g. breast cancer or haematology)
or treatment streams (such as medical or radiation oncol-
ogy). If there is more than one department/hospital which
shares common staff members, they will be considered one
site for the purpose of this study. This is necessary to
ensure that participating staff members are not exposed to
both Core and Enhanced implementation strategies.
Exclusion criteria
Cancer services will be excluded if they are unable to
commit to:
a) endorsing and enabling staff training for ADAPT
b) engaging with ADAPT staff for the 3-month
engagement and tailoring period
c) allowing a complete site profile audit and release of
their organisational chart
d) authorising release (with individual patient consent)
of Medical and Pharmaceutical Benefit (MBS/PBS)
provider information and statistics;
and if they do not have Wi-Fi/broadband/internet access
and/or an internet browser version that complies with
the ADAPT Portal requirements.
Recruitment: cancer services and staff
An initial meeting (face to face or via teleconference)
will be held, attended by representatives of the ADAPT
research team, the Head of the cancer service, and
representatives of the psychosocial, nursing, clinical trial
and IT staff. At this meeting, the study will be described
in detail, and potential interest in participation will be
ascertained. Interested cancer services will be asked to
identify a local ADAPT champion, and to sign an
ADAPT Research Participation Agreement.
All staff employed on a permanent or ongoing (6
months or more) basis, either full or part time or as a
visiting medical officer, in a role that provides clinical
care to patients with cancer or client focussed adminis-
trative support or IT/managerial support, will be invited
to participate in the study. Staff will be identified as part
of the organisation chart mapping exercise during site
engagement. Site champions will identify and approach
eligible staff, to whom they will explain the study. Inter-
ested staff will be contacted by the research team and
provided with a written information sheet and consent
form to sign.
A site, or individual cancer service staff member, may
withdraw from the study and elect to have their data
removed from the study database. If a site chooses to
withdraw prior to completion of baseline data collection,
and there is sufficient time within the study timeline, the
site will be replaced by a reserve list site pre-randomised
to the same study arm.
Recruitment: patients
All patients at participating sites receiving psychosocial
care related to their cancer diagnosis will be treated
according to the ADAPT CP as part of routine care
during the 12-month implementation period. If a patient
does not wish to complete screening on a particular
occasion (defer) or declines screening completely, this
will be recorded in the ADAPT Portal and noted within
the patient’s medical record, in line with usual record
keeping practices at participating cancer services.
Patients participating in the ADAPT CP will be asked
to give informed consent for the researchers to access their
medical records and/or Medicare and Pharmaceutical
Benefits Scheme (MBS/PBS) claims history for a period of
10 years to enable health economic analyses. Patients may
withdraw this consent at any time.
Interventions/groups
Sites will be randomised to a Core implementation arm
versus an Enhanced implementation arm to facilitate
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uptake of the ADAPT CP. All cancer services will
receive access to, and training to support use of, the
online resources developed to support ADAPT. These
resources (described in detail above) are the:
 ADAPT Portal
 ADAPT Health professional training
 ADAPT Patient education materials
 iCanADAPT Cognitive-behavioural Therapy
The Core implementation and Enhanced implementa-
tion arms will differ in the implementation strategies
used to support the use of ADAPT CP at their cancer
service. Specifically, these differences are:
 Core: These sites will receive implementation
strategies consistent with usual roll out of a clinical
pathway in the NSW health context, to inform staff
of the ADAPT CP and enable them to initiate use of
the ADAPT Portal and intervention resources. Once
the ADAPT Portal is launched and the
implementation phase has commenced, Core sites
will receive reporting feedback and audit reports at 4
weekly intervals and additional support from the
ADAPT team only at their request (a passive
approach).
 Enhanced: These sites will receive the same
implementation strategies as the core group, with
the addition of more prolonged, active engagement
of the ADAPT team, that will continue during the
12-month implementation phase. These additional
strategies will include monthly meetings to identify
training and support needs of local champions,
additional awareness activities, audit and feedback
reports prior to and midway through the
implementation phase summarised and presented
face-to-face by research staff to site staff, and other
tailored strategies to address the specific barriers
and facilitators in each site (an active approach).
The strategies, described in detail in Table 1, were
developed by the research team, comprising experts in
the fields of psycho-oncology and implementation
science, cancer services leaders, and consumers. A
literature review, NSW Health current implementation
practices, and the ADAPT barriers and enablers study
[23] guided the development of the strategies.
Study procedures and timeline
Randomisation will be performed by the study statistician
using online randomisation software (STATA). Allocation
concealment will be preserved; both sites and ADAPT
Program staff conducting assessments will remain blinded
until study completion. Following randomisation, sites will
undertake a 3-month period of engagement to clarify
study procedures, train staff in the ADAPT CP and use of
the ADAPT resources, and tailor the ADAPT Portal to
local site resources and preferences. Study sites will then
complete baseline (T0) staff questionnaires and interviews
to ascertain staff views on service and staff readiness to
adopt the ADAPT CP. The online questionnaires will be
available on RedCap (Research Electronic Data Capture)
[29] and automatically downloaded to a database to re-
duce possible bias. The ADAPT research team will
follow-up those participants who do not complete or
return their questionnaire within 2 weeks, with up to
three reminder emails or phone calls at different times of
the day. A subset of staff with key roles in implementing
the ADAPT CP will be invited to participate in an
audio-recorded semi-structured interview exploring their
views of the ADAPT CP, barriers and facilitators to its use
and site readiness.
Sites will then “go-live,” integrating the ADAPT CP
into clinical care for a 12-month implementation period.
Staff will be encouraged to introduce the ADAPT CP to
all patients as part of routine care, and on their verbal
consent, register them into the ADAPT Portal. Patients
will then be asked to access the ADAPT Portal for
efficient screening and data collection, information and
access to ADAPT resources. Staff will be asked to
respond to ADAPT emails and alerts for patients who
require further assessment and referral. ADAPT
research staff will administer Core versus Enhanced
implementation strategies as per randomisation during
this period.
Mid-way through the 12-month implementation
period (T1 at 6 months) and at the end of the imple-
mentation period (T2 at 12 months), questionnaire data
will again be collected from cancer service staff, and a
subset of cancer service staff will participate in an
audio-recorded semi-structured interview to ascertain
staff views on implementation outcomes, and awareness
of and perceived utility of the ADAPT CP implementa-
tion strategies.
Timing of enrolment, engagement, intervention and
data collection is shown in Table 2.
Case report forms (CRFs) in this study will take the
form of site profile forms, contact logs, implementation
strategy checklist and observational diaries, implementa-
tion strategy data psycho-social activity data and Medi-
care Data forms completed by ADAPT Program staff to
collect service level data and staff surveys completed by
cancer service staff participants. All other quantitative
data will be collected electronically via the ADAPT por-
tal. Additionally, the research team will conduct internal
audits by reviewing automated reports built into the
ADAPT Portal to ensure system functioning, correctness
and accuracy of data entry.
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Measures
Primary outcome
The primary outcome is site adherence to the ADAPT
CP, operationalised as the percentage of patients at each
site whose care is considered adherent to the ADAPT
CP, using data extracted from the ADAPT Portal. The
measure, guided by the literature on adherence [30],
captures for each patient, whether they received the
ADAPT CP components (screening, triage conversation,
referral, referral uptake check, progress review, discharge
summary, and rescreening) appropriate for their level of
anxiety and depression, expressed as a continuous score
of 0–100. Mean scores will be calculated for each site,
averaging scores for all patients. This continuous mean
score will be transformed into a binary score of adherent
(≥70% of patients experiencing ≥70% of appropriate
components) or non-adherent (< 70% of patients experi-
encing ≥70% of appropriate components), based on
accepted implementation targets [31, 32].
Secondary outcomes
ADAPT CP secondary outcomes will address the follow-
ing domains: acceptability, adoption, appropriateness,
feasibility, fidelity, cost and penetration, and sustainabil-
ity of the ADAPT CP, defined in large part by the
Proctor framework of implementation outcomes [33]
(see detail below and in Table 1). ADAPT implementa-
tion strategy outcomes will address similar domains, but
with reference to the degree to which implementation
strategies (Awareness Campaigns, Champions, Academic
Detailing and Support, Education, Reporting and
Technology) support the implementation of the ADAPT
CP.
Acceptability is operationalised as the perception of
cancer service staff that the ADAPT CP (1) and the
ADAPT implementation strategies (2) are agreeable,
palatable and satisfactory, the first in addressing anxiety
and depression in their client population, the second in
facilitating implementation. This will be measured
qualitatively during staff interviews.
Adoption of the ADAPT CP (1) is operationalised as
the proportion of patients at each site who are registered
and screened on the ADAPT Portal. Adoption of the
ADAPT implementation strategies (2), is operationalised
as mean staff ratings of how much they were aware of,
observed and used each implementation strategy,
collected via the staff questionnaire.
Appropriateness is operationalised as the extent to
which staff believe that the ADAPT CP has fit, relevance
and compatibility at the level of their setting, their role,
and the needs of their consumers, measured quantita-
tively by the Hands 4 U questionnaire [34] (items
adapted to the context of this study) and additional
study-developed items within the staff questionnaire.
Appropriateness will also be measured qualitatively in
staff interviews.
Feasibility, operationalised as the extent to which the
ADAPT CP is considered feasible by staff of each
service, given their different needs and resources, and
the degree of individual tailoring required to set up the
ADAPT Portal, will be measured qualitatively in
semi-structured interviews.
Direct costs of delivering the ADAPT implementation
strategies (in terms of research staff time and resources)
will be calculated from the research team logs. Costs of
developing, maintaining and delivering different compo-
nents of the ADAPT CP, will also be calculated. Patient
Table 1 Implementation strategies
Strategy Both Core and Enhanced implementation strategies arms Enhanced implementation strategies arm only
Awareness campaign • Roadshow presentation by ADAPT staff at the site
8 weeks before “go-live”
• Poster displayed prominently 4 weeks prior to and
at “go-live,” (T0)
• Email from site champion to all staff 1 week before
“go-live” (T0)
• Additional posters at 4-monthly intervals during
implementation
• Newsletters emailed to site staff at 2, 4, 6, 9 and
12 months
Champions • Champion identification and role definition
• Provision of email templates for champion to send staff
• Inclusion of champion contact details in all staff
communication
• Additional proactive contact with Champions at
monthly intervals to discuss progress, provide audit
reports and discuss additional implementation
strategies as needed
Academic detailing and support • Sites provide with a written report summarising change
readiness data from baseline staff interviews at T0
• Tailoring of the ADAPT Portal to site requirements during
engagement meetings
• Study close meeting with all key staff to discuss
sustainability of the ADAPT CP
• Sites provided with a verbal report of these data, at
T0, T1 and T2
• Quarterly review of ADAPT Portal configuration to
confirm allocated responsibilities and service tailoring
Reporting • Monthly written reports on Portal statistics • Presentation and highlighting of issues from monthly
reports in face-to-face meetings with site
Technological support • IT support for the ADAPT Portal
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health services use, including pharmaceutical prescrip-
tions related to anxiety and depression, will be ex-
tracted from Medicare MBS/PBS and hospital medical
records data. These data will be used to estimate
changes in health system resource use before and
after participating in the ADAPT CP, and to deter-
mine whether differences in adherence are associated
with differences in health system resource use and
overall costs.
Penetration is operationalised as the number of staff
and services who were aware of, and engaged with, the
ADAPT CP and implementation strategies.
Sustainability, defined as the extent to which the
ADAPT CP is maintained or institutionalized within a
service setting’s ongoing, stable operations, will not be
measured during the ADAPT Cluster RCT, as no data
will be collected beyond the 12 months implementation
phase. However, intention to sustain the ADAPT CP will
be elicited during T2 qualitative interviews. Further
funding will be sought to audit actual sustainability in
the future at participating sites, post the RCT.
Predictors of adherence, including staff attitudes to
the ADAPT CP, perceived social influence to enact it,
self-efficacy, organisational readiness and intention to
implement the ADAPT CP, will be assessed by the
Organisational Readiness to Change (ORIC) question-
naire [35], Hands4U questionnaire [34] and some
study-developed ADAPT organisational readiness items.
Potential confounders
Demographic and disease factors will be collected
including years in oncology practice and years in current
position (staff only); age, gender, marital status, educa-
tion, postcode, ATSI status (staff and patients); and
cancer type and stage of disease (patients only).
Table 2 Schedule of enrolment, engagement, intervention and data collection
Study period
Enrolment Engagement Allocation Intervention Costs retrieval


















Core X X X
Enhanced X X X
Assessments:
Primary outcome
Adherence: CP X X
Secondary outcomes
Acceptability X X X
Adoption X X
Appropriateness X X X
Feasibility X X X
Costs X X X X
Penetration X X
Sustainability X
ORIC, Hands4U, study-developed organisational readiness
items
X X X
Demographic & disease items X
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Additional secondary outcomes include the preva-
lence of anxiety and depression over time, accessed from
the ADAPT Portal.
Safety reporting
All adverse events (AEs) and serious adverse events
(SAEs) related to implementing the ADAPT CP will be
recorded concisely using standard terms.
The interventions being evaluated in this study are
targeted at cancer service staff. It is not envisaged that
cancer service staff will experience any adverse events.
In the unlikely occurrence that attendance at a training
or information session, completion of a survey or an
interview does result in an adverse event, the relevant
ethics committee will be notified. As screening and man-
agement of anxiety and depression will be introduced as
standard practice, the reporting of adverse events related
to anxiety and depression will not be reported as a study
related AE event. There are no safety endpoints and no
criteria for early study termination.
Data management
All data will be stored in locked filing cabinets in a
locked office at The University of Sydney or scanned
and stored in password protected files and kept at the
University of Sydney on a secure server. Electronic data
will be password protected and kept at The University of
Sydney on a secure server, which is backed up daily.
Study-related records for all participants will be retained
in a secure storage facility for at least 7 years after the
completion of the research, according to the National
Health and Medical Research Council requirements.
These include: participant files, study protocol, signed
consent forms, CRFs, questionnaires, ethics correspond-
ence and approvals, other regulatory documentation,
and other documents pertaining to the conduct of the
study. All relevant documentation according to the Data
Management Plan will be held by the lead investigator at
each participating site for the duration of the study. This
study will adhere to PoCoG’s quality assurance
processes, including adherence to standard operating
procedures and regularly reporting of study progress to
the organisation.
Statistical methods
Sample size and justification
Power for primary endpoints Based on cancer registry
data for NSW (2009) (https://www.cancerinstitute.org.au/
data-research/data-held-by-cinsw/nsw-cancer-registry),
approximately 37,525 patients in NSW will be
diagnosed with cancer in NSW each year. Based on prior
epidemiological studies, 42–45% and 35–37% of these will
experience mild depression or mild anxiety, respectively
[3, 36, 37] and 22–36% and 20–30% will experience mod-
erate to severe depression and/or anxiety respectively.
Based on incidence and prevalence of cancer in NSW,
a conservative estimate of 464 screening events per site
(total sample of 5568 screening events in 12 sites), there
is at least 80% power to detect a difference in adherence
rates of 30% in the Core and 60% in the Enhanced arm
using a two-tailed test with Type 1 error rate of 5%. The
sample size has been adjusted for the variance inflation
factor due to the clustered design and can accommodate
an intraclass correlation coefficient (ICC) as high as 0.14
to achieve 80% power and 0.10 to achieve 90% power
[38, 39]. Although estimates of the ICC are not available,
we expect the ICC will be within this range. Based on
the Cancer Institute figures, we do not envisage any dif-
ficulty in recruiting the required sample for this study.
Note that the number of screening events and projected
sample size and power may be revised based on screen-
ing at the first three services.
Power for secondary endpoints Secondary outcomes
will use data from either the ADAPT Portal, relating to
patient activity through the ADAPT CP, MBS/PBS, staff
surveys, staff interviews, or ADAPT research team
observational records. Given the expected large sample
size of 5568 patients, power should be adequate to test
the patient activity related secondary outcomes. For sec-
ondary outcomes using staff reported data we anticipate
a minimum of 10 staff per site, with 12 sites participat-
ing (120) in total.
Primary analyses
The primary analysis will be conducted using a general-
ized estimating equations (GEE) approach to account for
the correlation of outcomes within a cluster (site) using
an exchangeable covariance structure and a bias correc-
tion factor to account for the small number of clusters
[39]. The dependent variable will be clinical pathway
adherence and the exposure variable will be the inter-
vention status (core versus enhanced). The unit of
analysis will be at the patient level to accommodate the
weighting required by unequal cluster (site) sizes. Other
independent variables will be added to the model if they
are independently associated with adherence and/or
their inclusion in the model changes the linear coeffi-
cient of the intervention effect by more than 20% in
absolute value (i.e. effect modifiers).
Secondary analyses
Secondary outcomes for this study include the collection
of qualitative and quantitative data. Qualitative data will
be analysed using content and thematic analysis. This
will apply to data collected from (i) cancer service staff
interviews and (ii) observational diary and contact log
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data captured by the ADAPT research team. Qualitative
data will be coded by researchers trained in qualitative
methods. Initial themes and subthemes will be identified
and discussed by members of the research team to establish
a coding tree. Transcripts and/or diaries and/or contact
logs will then be coded by a minimum of two coders.
Coding discrepancies will be resolved by discussion.
Quantitative data will be analysed using descriptive
statistics, univariate and multivariate analyses. Analyses
will be conducted at patient level and site level. General-
ized estimating equations (GEE) will also be used.
Compliance with regulatory guidelines
This study will be conducted in compliance with the:
 International Conference on Harmonisation of
Technical Requirements for Registration of
Pharmaceuticals for Human Use Good Clinical
Practice (ICH-GCP),
 The National Health and Medical Research Council
National Statement on Ethical Conduct in Human
Research,
 The Australian Code for the Responsible Conduct of
Research,
 Therapeutic Goods Administration’s Australian
Clinical Trial Handbook, and
 Declaration of Helsinki.
Discussion
This study will advance the field by identifying the level
of implementation support, and resource use (Core
versus Enhanced) required to effectively achieve adher-
ence to a clinical pathway for anxiety and depression in
cancer patients (ADAPT CP). It will be the first study
internationally to explore this research question through
a rigorous cluster randomised controlled trial, where
sites are randomised to different implementation strat-
egies. The costs and consequences of the implementa-
tion strategies will also be evaluated. The study will
describe predictors of adherence, including staff and
service readiness for change, staff attitudes, self-efficacy,
social influence and intention to implement the CP, and
staff, patient and service characteristics. A strength of
the study is that adherence data, as well as potential pre-
dictors and cost data, will be collected longitudinally,
allowing these factors to be explored over time.
The ADAPT CP is relevant to all cancer types and
cancers of any stage. The ADAPT Cluster RCT trial will
recruit cancer services providing care to a range of
tumour streams, and it is intended that the ADAPT CP
will be applied to all patients within these services,
including those treated with curative intent and those
treated palliatively. Furthermore, randomisation will be
stratified by size of service to ensure inclusion of both
large and small cancer services, and those within both
metropolitan and rural/regional areas, to determine the
implementation strategies required across a range of ser-
vices likely to vary in their resources and culture. While
this study is restricted to the ADAPT CP, the findings
will be generalisable to other CPs, providing a broader
impact on health service change.
A qualitative component is included in this study to
capture the complexity of the barriers and facilitators
influencing uptake of the ADAPT CP, and response to
the ADAPT implementation strategies. These are
expected to vary across sites with different clinical and
research cultures, resources, patient populations and
staffing profiles, and qualitative research has value in
understanding these issues.
The two levels of implementation effort tested here
(Core implementation strategy versus Enhanced imple-
mentation strategy) include multiple types of implemen-
tation strategies, and it will not be possible to determine
whether one versus another has had the greatest impact.
However, we will be able to investigate potential media-
tors and moderators of intervention success, to guide
hypotheses for investigation in future studies.
With an increased focus on implementation of
evidence that has been costly to accrue, and the poten-
tial to improve patient outcomes immediately, clinical
pathways are likely to form the basis for care in a grow-
ing number of health systems. Clinical Pathways have
great potential for enhancing the translation of evidence
into practice, however health system policy and planning
require accurate data on the costs and size of implemen-
tation effort required to ensure their success. Armed
with such data, health service administrators can better
plan introduction of clinical pathways within current
budget constraints. Thus, this study will provide infor-
mation critical to improving healthcare outcomes.
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